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Abstract
Introduction: Some conﬂicting results have been published about the relationship between TNF-
-308 gene polymorphism and chronic obstructive pulmonary disease (COPD). The aim of this
study was to determine whether TNF--308 gene polymorphism was associated with smoking-
related COPD and whether it was associated with pulmonary function parameters (PFTs), body
mass index (BMI), and prognosis.
Methods: We studied the frequencies of TNF--308 gene polymorphism in 90 male subjects
(60 subjects with COPD and 30 healthy smokers) in a Caucasian population.
Results: There was no signiﬁcant difference in the frequency of G/G and G/A gene poly-
morphisms in the COPD group compared with control subjects (p > 0.05). We compared COPD
patients as G/A gene polymorphism and G/G gene polymorphism; the PFTs and BMI before
and after one year were not statistically signiﬁcant (p > 0.05). Also, the exacerbation and
hospitalization data of COPD patients were not signiﬁcant between these groups.
Conclusion: In conclusion, there was no difference between smoking-related COPD and the
control group according to TNF -308 gene polymorphism in a Caucasian population. In addi-
tion, it was shown that important determinants of prognosis of COPD such as FEV1, BMI, COPD
exacerbation and hospitalization were not associated with TNF--308 gene polymorphism.
© 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights
reserved.
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PALAVRAS-CHAVE
Doenc¸a pulmonar
obstrutiva crónica;
Genética;
Polimorﬁsmo;
Factor de necrose
tumoral alfa
Estará o polimorﬁsmo do gene TNF- relacionado com a func¸ão pulmonar e o
prognóstico determinados pelo VEMS, IMC, exacerbac¸ões e hospitalizac¸ões em
doentes com DPOC associados ao tabagismo numa populac¸ão turca?
Resumo
Introduc¸ão: Foram publicados alguns resultados contraditórios sobre a relac¸ão entre o polimor-
ﬁsmo do gene TNF- -308 e a doenc¸a pulmonar obstrutiva crónica (DPOC). O objectivo deste
estudo foi determinar se o polimorﬁsmo do gene TNF- -308 estava associado à DPOC ligada
ao tabagismo e se foi associado aos parâmetros de func¸ão pulmonar (PFTs), índice de massa
corporal (IMC), e prognóstico.
Métodos: Estudámos as frequências do polimorﬁsmo do gene TNF- -308 em 90 indivíduos do
sexo masculino (60 indivíduos com DPOC e 30 fumadores saudáveis) numa populac¸ão caucasiana.
Resultados: Não houve uma diferenc¸a signiﬁcativa na frequência de polimorﬁsmos genéticos
G/G e G/A no grupo de DPOC, em comparac¸ão com o grupo de controlo (p>0,05). Comparámos
os doentes com DPOC como polimorﬁsmo genético G/A e polimorﬁsmo genético G/G; os PFTs
(parâmetros de func¸ão pulmonar) e o IMC (índice de massa corporal) antes e depois de um ano
não eram estatisticamente signiﬁcativos (p>0,05). Da mesma forma, os dados de agravamento
e hospitalizac¸ão dos doentes com DPOC não eram signiﬁcativos entre estes grupos.
Conclusão: Em conclusão, não existiu uma diferenc¸a entre o grupo com DPOC ligada ao tabag-
ismo e o grupo de controlo, de acordo com o polimorﬁsmo do gene TNF  -308, numa populac¸ão
caucasiana. Além disso, foi mostrado que determinantes importantes do prognóstico da DPOC,
tal como VEMS, IMC, exacerbac¸ões da DPOC e hospitalizac¸ão não estavam associados ao polimor-
ﬁsmo do gene TNF- -308.
© 2013 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L.U. Todos os
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Patients were excluded if they had had an exacerbation ofdireitos reservados.
ntroduction
igarette smoking is the most common and important cause
f chronic obstructive pulmonary disease (COPD). However,
OPD develops in only 10--15% of smokers.1 In addition, a
amilial predisposition for COPD and lung function is well
nown.2,3 These ﬁndings suggest that genetic factors are
esponsible for COPD. Alpha-1 antitrypsin deﬁciency is the
est-known genetic risk factor for COPD, but such cases are
stimated to account for only 1--2%.4
Tumor necrosis factor (TNF)- is a cytokine primar-
ly derived from macrophages. Increased concentrations
f TNF- have been found in induced sputum, bronchoal-
eolar lavage ﬂuid, and bronchial biopsies from patients
ith COPD compared with healthy smokers.5--7 These ﬁnd-
ngs have led researchers to further work on TNF-.
genomic polymorphism resulting in the substitution of the
ucleotide adenine (A) for guanine (G) at position-308 within
regulatory region of the TNF- locus was discovered in
992.8 This polymorphism at position-308 of the TNF- gene
howed elevated TNF- secretion and blood levels in some
tudies.9,10
It is necessary to clarify the effects of genetic poly-
orphisms of the TNF- gene promoter region for the
evelopment of COPD and disease progression. Some
onﬂicting results have been published about the relation-
hip between TNF--308 gene polymorphism and COPD. A
eta-analysis of twenty four studies showed that TNF--
08 gene polymorphism is associated with an increased risk
f COPD in the Asian population, but this relationship is
ot signiﬁcant in the Caucasian population.11 Although pre-
ious reports showed that the FEV1 and BMI values were
C
i
nower in COPD patients than in smoker controls, there was
o signiﬁcant difference among G/G, G/A and A/A gene
olymorphisms in COPD patients.12--14 In a report that eval-
ates the prognosis of COPD and TNF- gene polymorphism,
OPD exacerbation was found to be the most common cause
f death.12 The aims of the present study were to deter-
ine whether TNF--308 gene polymorphism was associated
ith smoking-related COPD and whether it was associated
ith pulmonary function parameters (PFTs), body mass index
BMI), and prognosis in a Caucasian population.
ethods
ubjects
he study was approved by the Research Ethics Committee
f Erciyes University School of Medicine in Kayseri, Turkey
nd all subjects gave written informed consent. Ninety sub-
ects were enrolled from August 2010 to December 2011. The
atient group was recruited from the Pulmonary Outpatient
epartment. It consisted of 60 male adults with COPD. The
iagnosis of COPD was made according to the Global Initia-
ive for Chronic Obstructive Lung Disease standards.15 The
riteria of enrollment were as follows: (1) >40 years old,
2) a smoking history of 20--80 pack-years, (3) avail-
ble spirometry data for the previous year, (4) post-
ronchodilator FEV1/FVC <70%, and (5) patient’s consent.OPD within the previous 6 weeks and signiﬁcant reversibil-
ty (FEV1 or FVC > 12% baseline and/or 200ml) to 2.5mg
ebulized salbutamol.
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Table 1 Demographic characteristics and pulmonary test parameters of the COPD patients and healthy control groups.
COPD (n = 60) Controls (n = 30) p
Age (years) 60± 10 54± 7 0.002
Smoking (pack-years) 45± 17 41± 19 0.316
Current smoking, n (%) 5 (8%) 23 (77%) <0.001
FEV1 (% predicted) 51± 17 98± 11 <0.001
FEV1/FVC (% predicted) 52± 10 78± 4 <0.001
FEF 25--75 (% predicted) 20± 10 82± 25 <0.001
BMI (kg/m2) 26± 4 29± 4 0.001
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iValues are expressed as mean± SD or as absolute numbers. COP
volume in 1 s, FVC = Forced vital capacity, FEF25--75% = Forced exp
The previous year’s PFTs and BMI (calculated as weight in
kg divided by the square of height in meters) were recorded
from ﬁles. The annual number of hospitalizations and COPD
exacerbations were examined during the last year. Exacer-
bation of COPD was deﬁned as ‘‘an event in the natural
course of the disease characterized by a change in the
patient’s baseline dyspnea, cough and/or sputum that is
beyond normal day-to-day variations, is acute in onset and
may warrant a change in regular medication’’.15 New PFTs
were performed by experienced technicians and BMI was
calculated.
The control group consisted of 30 male chronic heavy
smokers with normal lung function who were recruited
randomly from the smoking cessation clinic. The inclusion
criteria were as follows: (1) male older than 40 years of
age, (2) heavy smoker with a smoking history of 20--80 pack-
years, (3) post-bronchodilator FEV1/FVC ratio > 70%, FEV1%
predicted > 80%, and FVC % predicted > 80%, (4) no other pul-
monary disease.
Spirometer
All PFTs were performed by experienced lung function tech-
nicians with the same standard spirometer (Vmax20 system;
SensorMedics, Yorba Linda, CA, USA) according to Amer-
ican Thoracic Society (ATS) recommendations.16 The best
FVC measurement was recorded along with FEV1 and the
FEV1/FVC calculations.
Genotyping protocol
Three milliliters of whole peripheral blood was obtained
from each study participant by phlebotomy into a tube con-
taining ethylene diamine tetra-acetic acid (EDTA). DNA was
extracted promptly using a MagNA Pure LC DNA Isolation
Kit I (Cat. No. 03003990001, Ver. 17.0) supplied by Roche
(Mannheim, Germany).
TNF alpha-308 promoter gene polymorphism (rs1800629)
was genotyped using the LightCycler real-time PCR system.
The primers and hybridization probe for genotyping the -
308 promoter polymorphism were designed by and obtained
from Tib MolBiol GmbH, Berlin, Germany. The PCR reaction
was carried out using the LightCycler real-time PCR machine
480 II (Roche Diagnostics GmbH, Mannheim, Germany), with
software version 1.5.0. A reaction volume of 20l (with 2l
of DNA Master Mix, 1l of primers probe, 1.6l of 25mM
M
(
phronic obstructive pulmonary disease, FEV1 = Forced expiratory
ry ﬂow 25--75%, BMI = Body mass index.
gCl2, 10.4l H2O and 5l genomic DNA (10 ng)) was ampli-
ed in 96-well plates using the FastStart LC 480 II genotyping
aster kit (Roche Diagnostics GmbH). The PCR protocol for -
08 promoter polymorphism consisted of initial denaturation
t 95 ◦C for 10min, followed by 45 cycles of denaturation
95 ◦C for 10 s, 4.4 ◦C/s), annealing (60 ◦C for 10 s, 2.2 ◦C/s)
nd elongation (72 ◦C for 10 s, 4.4 ◦C/s). This was followed by
elting curve analysis consisting of 1 cycle at 95 ◦C for 30 s
4.4 ◦C/s), 40 ◦C for 2min (1.5 ◦C/s) and a temperature rise
o 75 ◦C at a slope of 0.19 ◦C/s with continuous measurement
f ﬂuorescence.
tatistical analysis
PSS software (Statistical Package for the Social Sci-
nces, version 15.0, SSPS Inc, Chicago, IL, USA) was used
or statistical analyses. The distribution of continuous
ariables for normality was tested with the One-Sample
olmogorov--Smirnov test and data are presented as
ean± standard deviation (S.D.) or median and interquar-
ile ranges, as appropriate. Demographic characteristics
nd parameters were compared using the Student t-test or
ann--Whitney U test for the continuous variables, where
ppropriate. Categorical variables were analyzed by the
2-test. According to groups, the before and after values
f the quantitative variables were assessed by the mean
aired-sample t-test. The power of the study based on the
ene polymorphism was 0.068 for (with alpha error of 0.05).
ifferences were considered statistically signiﬁcant when
< 0.05.
esults
omparison of COPD group and control group
he characteristics of the COPD (n = 60) and the control
roups (n = 30) are summarized in Table 1. The COPD patients
ere older (60± 10 vs. 54± 7 years, p < 0.05) than the con-
rol group but had a similar pack-year history (45± 17 vs.
1± 19 pack-years, p > 0.05). PFTs (FEV1%, FEV1/FVC, FEF
5--75%) in the control group were near normal and signif-
cantly greater than those of the COPD group (p < 0.001).
ean BMI was also signiﬁcantly lower in the COPD group
26± 4 vs. 29± 4 kg/m2, p = 0.001).
The genotype frequencies of TNF--308 gene polymor-
hisms in the COPD group were compared with those in
308 N. Özdog˘an et al.
Table 2 Genotype frequencies in patient and control
groups.
TNF--308
Genotype
COPD
(n = 60) (%)
Controls
(n = 30) (%)
p
G/G 44 (73) 24 (80) >0.05
G/A 16 (27) 6 (20)
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Table 4 The exacerbation and hospitalization of COPD
patients by grouped as gene polymorphism.
G/A (n = 16) G/G (n = 44) p
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ontrol subjects. Forty-four (73%) patients had G/G and 16
27%) patients had G/A gene polymorphisms in the COPD
opulation; 24 (80%) patients had G/G and 6 (20%) patients
ad G/A gene polymorphisms in the control group. AA geno-
ypes were not determined in any patient in the two groups.
here was no signiﬁcant difference in the frequency of G/G
nd G/A genotypes in the COPD population compared with
ontrol subjects (p > 0.05) (Table 2).
omparison of COPD patients grouped by genotype
n COPD patients, the mean age and smoking status of
atients were compared as groups of TNF--308 G/A gene
olymorphism (n = 16) and G/G gene polymorphism (n = 44).
he mean age [61± 11 (G/A)/60± 10 years (G/G)], the
mount of smoking [45± 17 (G/A)/45± 17 pack-years (G/G)]
nd active smoking [0 (G/A)/5 (G/G)] was not statistically
igniﬁcant in these groups (p > 0.05). Also, a comparison of
FTs and BMI before and after one year were not statistically
igniﬁcant (p > 0.05). Table 3 shows the comparison of PFTs
nd BMI in both groups.
xacerbation and hospitalization data of COPD
atients
he exacerbation and hospitalization data of COPD patients
re summarized in Table 4. Eleven (69%) patients who had
/A gene polymorphism and 27 (61%) patients who had G/G
ene polymorphism in the COPD group had acute COPD exac-
rbation in the past year. Six (38%) patients with G/A gene
olymorphism and 14 (32%) patients with G/G gene poly-
orphism were hospitalized because of COPD exacerbation.
either of these differences were statistically signiﬁcant
p > 0.05).
C
s
Table 3 Comparison of PFTs and BMI before and after one year g
G/A (n = 16)
Before After p Befo
FEV1 (L) 1.45 ± 0.50 1.45 ± 0.58 0.947 1.59
FEV1 (%) 47.7 ± 15.4 47.3 ± 15.7 0.866 52.4
FEV1/FVC (%) 50.9 ± 10.8 51.4 ± 10.6 0.835 52.2
BMI (kg/m2) 24.9 ± 3.6 25.1 ± 3.8 0.721 26.1
* Comparison of before values of G/A and G/G group.
** Comparison of after values of G/A and G/G group.Exacerbation 11 (69%) 27 (61%) >0.05
Hospitalization 6 (38%) 14 (32%) >0.05
iscussion
he present study demonstrates that there is no differ-
nce in the frequency of G/A and G/G gene polymorphism
n patients with COPD compared to healthy, smoking con-
rol subjects in a Caucasian population. Many studies have
hown an association between COPD and TNF--308 gene
olymorphism in an Asian population.17--20 However, in a Cau-
asian population, although studies have been conducted
n different countries, most of them did not show any
ssociation; this was similar to our results.12,21--30 A large
amily study from a Boston early-onset COPD study and
nother American study are the only two studies to show
n association between COPD and TNF--308 polymorphism
n a Caucasian population.13,31 In addition, a study from
ur country recently showed a signiﬁcant difference among
OPD stages in terms of TNF- 308 G/A polymorphism.32
owever, a meta-analysis of data for 6118 subjects also
howed that TNF-308 gene polymorphisms were signiﬁcantly
ssociated with an increased risk of COPD among an Asian
opulation but not among a Caucasian population.11 In this
ituation, it seems that polymorphisms in the TNF--308
ene that stimulate the production of cytokines are not
ajor genetic determinants for the development of COPD
n most of the Caucasian population.
The major etiologic factor for the development of COPD
s cigarette smoking. The risk of COPD development among
eople with a similar history of smoking may be different
ue to genetic predisposition and/or lifestyles. In a study
nvestigating the association between antioxidant genes and
OPD, the deﬁnition of ‘‘resistant smoker’’ was used for
mokers who did not develop COPD.33 Therefore, we identi-
ed individuals with a smoking history of 20--80 pack-years
nd created similar patient and control groups. TNF--308
ene polymorphism was found to be ineffective in the devel-
pment of COPD in these groups which had a similar smokingThe second major ﬁnding in the present study is that
OPD patients with G/A and G/G gene polymorphism had
imilar PFTs (FEV1, FEV1%, FEV1/FVC) before and after one
rouped by gene polymorphism in patients with COPD.
G/G (n = 44) p1* p2**
re After p
± 0.57 1.64 ± 0.64 0.309 0.376 0.298
± 17.5 54.8 ± 20.1 0.154 0.345 0.185
± 9.8 53.0 ± 10.4 0.364 0.661 0.605
± 4.6 25.9 ± 4.9 0.428 0.375 0.548
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year evaluation. The FEV1 value was the most commonly
used parameter for monitoring disease progression.15 Only
one report exists that evaluates the prognosis of TNF--
308 gene polymorphism in COPD patients.12 Keatings et al.
showed that AA homozygous patients had less reversible air-
ﬂow obstruction and a signiﬁcantly greater mortality (both
all-cause and respiratory deaths) on follow-up despite a
shorter cigarette smoking history. In another study, the
homogenous A genotype in COPD patients was accompanied
by a signiﬁcant reduction in the mean values of the post-
bronchodilator FEV1, FEV1/FVC and FEF25/75% of predicted
compared to heterozygous G/A genotypes in COPD.30 How-
ever, in the present study, there were no patients with A/A
polymorphism for comparison purposes.
Another parameter that was shown to have prognostic
importance in patients with COPD was BMI.34 In a study by
Wilson et al., BMI was shown to be an important prognostic
factor after FEV1 in male patients with COPD.35 Further-
more, low BMI was shown to be independently associated
with reduced survival in patients with severe COPD.36 In the
present study, BMI was signiﬁcantly lower in patients with
COPD than in the healthy smoker control group. When we
examined the effect of the TNF--308 gene on BMI, neither
the current BMI nor the BMI of the previous year were sta-
tistically signiﬁcant between the patients with G/A and G/G
gene polymorphisms.
The most important limitation of this study was the low
number of patients. In addition, mortality was not examined
in the present study. No patients had A/A gene polymor-
phism, so we have no data about A/A gene polymorphism in
our population.
Conclusion
In conclusion, there was no difference between smoking-
related COPD and control group according to TNF -308 gene
polymorphism in a Caucasian population. In addition, it was
shown that important determinants of prognosis of COPD
such as FEV1, BMI, COPD exacerbation and hospitalization
were not associated with TNF--308 gene polymorphism.
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